Optimind Pharma (XCNQ:OMND) Debt-to-Asset : 0.71 (As of Nov. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Optimind Pharma Debt-to-Asset?

Optimind Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.57 Mil. Optimind Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Optimind Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Nov. 2023 was C$0.80 Mil. Optimind Pharma's debt to asset for the quarter that ended in Nov. 2023 was 0.71.

Optimind Pharma Debt-to-Asset Historical Data

The historical data trend for Optimind Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optimind Pharma Debt-to-Asset Chart

Optimind Pharma Annual Data

Trend

Feb22

Feb23

Debt-to-Asset

0.04

0.45

Optimind Pharma Quarterly Data
	Jun21	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Debt-to-Asset	Get a 7-Day Free Trial			0.14	0.45	0.57	0.71	0.71

Competitive Comparison of Optimind Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Optimind Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Optimind Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Optimind Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Optimind Pharma's Debt-to-Asset falls into.

Optimind Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Optimind Pharma's Debt-to-Asset for the fiscal year that ended in Feb. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.532	+	0.081)	/	1.354
	=	0.45

Optimind Pharma's Debt-to-Asset for the quarter that ended in Nov. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.571	+	0)	/	0.8
	=	0.71

Optimind Pharma (XCNQ:OMND) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Optimind Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Optimind Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Optimind Pharma (XCNQ:OMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 - 77 King Street West, TD Centre, North Tower, PO Box 95, Toronto, ON, CAN, M5K 1G8

Website

https://www.optimindpharma.com

Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities.

Optimind Pharma (XCNQ:OMND) Headlines

No Headlines